IL305665A - Bifunctional conjugates of galactose-deficient immunoglobulins - Google Patents
Bifunctional conjugates of galactose-deficient immunoglobulinsInfo
- Publication number
- IL305665A IL305665A IL305665A IL30566523A IL305665A IL 305665 A IL305665 A IL 305665A IL 305665 A IL305665 A IL 305665A IL 30566523 A IL30566523 A IL 30566523A IL 305665 A IL305665 A IL 305665A
- Authority
- IL
- Israel
- Prior art keywords
- optionally substituted
- groups
- group
- moiety
- independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163159383P | 2021-03-10 | 2021-03-10 | |
| PCT/US2022/019658 WO2022192478A1 (en) | 2021-03-10 | 2022-03-10 | Bifunctional degraders of galactose-deficient immunoglobulins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL305665A true IL305665A (en) | 2023-11-01 |
Family
ID=83227063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL305665A IL305665A (en) | 2021-03-10 | 2022-03-10 | Bifunctional conjugates of galactose-deficient immunoglobulins |
Country Status (11)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12023553152A1 (en) * | 2021-05-17 | 2024-03-11 | Biohaven Therapeutics Ltd | Compositions including conjugated therapy enhancers |
| JP2024524614A (ja) | 2021-07-14 | 2024-07-05 | ライシア セラピューティクス, インコーポレイテッド | Asgpr細胞表面受容体結合化合物及びコンジュゲート |
| CN121038815A (zh) * | 2023-04-29 | 2025-11-28 | 拜奥海芬治疗学有限公司 | 半乳糖缺陷型免疫球蛋白的双功能降解剂 |
| WO2026083257A1 (en) | 2024-10-14 | 2026-04-23 | Biohaven Therapeutics Ltd. | Antigen-specific degraders of immunoglobulin a and their uses |
| WO2026120177A1 (en) | 2024-12-06 | 2026-06-11 | Ascendis Pharma A/S | Novel long-acting degrader conjugates |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8440191B2 (en) * | 2005-11-18 | 2013-05-14 | Tufts Medical Center | Clearance of abnormal IGA1 in IGA1 deposition diseases |
| DK2991683T3 (da) * | 2013-05-02 | 2019-11-04 | Glykos Finland Oy | Konjugater af et glykoprotein eller en glykan med en toksisk ladning |
| CA2946064C (en) * | 2014-02-21 | 2023-09-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Glycotargeting therapeutics |
| RU2696490C2 (ru) * | 2014-05-19 | 2019-08-02 | Пфайзер Инк. | Замещенные-6,8-диоксабицикло[3.2.1.]октан-2,3-диольные соединения в качестве агентов, нацеленных на ASGPR |
| CA3134610A1 (en) * | 2018-04-09 | 2019-10-17 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
-
2022
- 2022-03-10 WO PCT/US2022/019658 patent/WO2022192478A1/en not_active Ceased
- 2022-03-10 US US18/548,113 patent/US20240309114A1/en not_active Abandoned
- 2022-03-10 CA CA3211335A patent/CA3211335A1/en active Pending
- 2022-03-10 KR KR1020237033102A patent/KR20230154900A/ko active Pending
- 2022-03-10 EP EP22767951.1A patent/EP4304579A4/en active Pending
- 2022-03-10 CN CN202280020292.8A patent/CN116997337A/zh active Pending
- 2022-03-10 BR BR112023017702A patent/BR112023017702A2/pt unknown
- 2022-03-10 MX MX2023010424A patent/MX2023010424A/es unknown
- 2022-03-10 AU AU2022232620A patent/AU2022232620A1/en active Pending
- 2022-03-10 IL IL305665A patent/IL305665A/en unknown
- 2022-03-10 JP JP2023555333A patent/JP2024509282A/ja active Pending
-
2026
- 2026-01-15 US US19/449,561 patent/US20260146106A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260146106A1 (en) | 2026-05-28 |
| JP2024509282A (ja) | 2024-02-29 |
| BR112023017702A2 (pt) | 2023-12-12 |
| CA3211335A1 (en) | 2022-09-15 |
| MX2023010424A (es) | 2023-09-18 |
| EP4304579A4 (en) | 2026-06-10 |
| US20240309114A1 (en) | 2024-09-19 |
| KR20230154900A (ko) | 2023-11-09 |
| WO2022192478A1 (en) | 2022-09-15 |
| CN116997337A (zh) | 2023-11-03 |
| AU2022232620A1 (en) | 2023-09-21 |
| EP4304579A1 (en) | 2024-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022192478A1 (en) | Bifunctional degraders of galactose-deficient immunoglobulins | |
| JP7617974B2 (ja) | シクロデキストリンタンパク質薬物コンジュゲート | |
| CN112261954B (zh) | 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐 | |
| KR102938500B1 (ko) | 항체 약물 접합제용 친수성 링커 | |
| RU2668560C2 (ru) | Конъюгированная вакцина на основе пептида антигена wt1 | |
| JP7587240B2 (ja) | 抗体-ペイロードコンジュゲートの調製のための化合物及びその使用 | |
| IL274236A (en) | Proline-fastened peptides and their uses | |
| IL274651A (en) | Glucocorticoid receptor agonist and immunoconjugates thereof | |
| CN114728073A (zh) | 药物从生物活性化合物的内化缀合物的选择性释放 | |
| CN120835793A (zh) | 用于降解自身抗体的溶酶体靶向双功能分子 | |
| CN121038815A (zh) | 半乳糖缺陷型免疫球蛋白的双功能降解剂 | |
| JP2021513990A (ja) | 疎水性アウリスタチンf化合物およびそのコンジュゲート | |
| IL315341A (en) | METHOD FOR PRODUCING Fc-CONTAINING MOLECULE | |
| AU2019350536B2 (en) | Sulfomaleimide-based linkers and corresponding conjugates | |
| KR20240012381A (ko) | 세포독성제를 전달하기 위한 mate 기술을 사용한 항체 약물 접합체 | |
| US20240383961A1 (en) | Conjugated antibodies for treating diseases | |
| WO2024048490A1 (ja) | 変異Fc領域を含む抗体薬物コンジュゲート | |
| KR101536037B1 (ko) | 아포리포단백질을 포함하는 항체-약물 결합체 | |
| WO2022097500A1 (ja) | ペプチド架橋剤及び当該架橋剤で架橋された架橋ペプチド | |
| EP2115001A1 (en) | Coupling of antibody polypeptides at the c-terminus | |
| WO2026026939A1 (zh) | 抗cd74抗体、抗体-药物缀合物及其制备方法和用途 | |
| WO2025111600A1 (en) | Compositions and methods for lipidated peptide-based modulators of hla-e | |
| CA3270680A1 (en) | ANTIBODY-DRUG CONJUGATE COMPRISING AN ANTI-CLAUDIN 18.2 ANTIBODY AND RELATED THERAPEUTIC USE FOR CANCER | |
| HK40117761A (en) | Antibody-drug conjugates targeting folate receptor alpha and methods of use | |
| CN120659785A (zh) | Tlr7激动剂及其抗体-药物缀合物 |